secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2022-01-27T23:59:59+00:00
Accession:  0001558370-22-000487
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics: updated UNITY-CLL OS data improves but FDA imposes partial clinical hold on U2 studies
--------------------------------------------------------------------------------

- Updated OS hazard ratio improved vs preliminary 1.23; still not statistically significant (Sep 2021 cutoff).
- FDA placed partial clinical hold on select U2 studies; no new enrollment, existing patients continue after reconsent.
- Partial hold based on same data as ODAC meeting scheduled for March/April 2022; no update expected before ODAC.
- Company nearing FDA submission of updated OS analysis; interim OS results may change as more events occur.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000155837022000487/0001558370-22-000487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000155837022000487/tgtx-20220127x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-000487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer